Cervical cancer represents a leading cause of oncological mortality among women worldwide, especially across developing healthcare ecosystems. Among these malignancies, cervical squamous cell carcinoma constitutes the vast majority of all registered clinical presentations. Clinicians routinely administer cisplatin-based chemoradiotherapy as the gold standard curative protocol. However, cellular chemoresistance frequently compromises treatment success, fostering disease recurrence and unfavorable clinical outcomes.

The Challenge of Chemotherapy Resistance in Cervical Malignancies

Platinum compounds like cisplatin induce cytotoxic lethality by forming covalent DNA adducts that disrupt transcription and replication. Consequently, heavily damaged malignant cells trigger apoptotic pathways. However, cervical cancer cells regularly develop multi-layered defense mechanisms that neutralize platinum genotoxicity. For instance, enhanced drug efflux, amplified antioxidant scavenging, and accelerated nucleotide excision repair diminish therapeutic efficacy. As a result, many patients encounter disease progression despite receiving maximum tolerable cisplatin dosages.

In regions with high disease incidence, chemoresistance poses a formidable therapeutic hurdle. Although initial tumour reduction occurs frequently, recurrent lesions demonstrate aggressive biology and cross-resistance to standard cytotoxic agents. Furthermore, subsequent systemic regimens offer limited survival improvements while causing substantial physiological toxicity. Clinicians therefore need accurate molecular biomarkers to identify chemoresistant phenotypes before primary treatment begins. In addition, clarifying the regulatory networks governing drug tolerance provides critical avenues to design synergistic therapeutic protocols.

Identification of circMCM3 as an Adverse Prognostic Driver

Circular RNAs represent covalently closed, single-stranded non-coding RNA molecules that lack free terminal ends. Because of this structure, they resist exonuclease degradation and exhibit exceptional intracellular stability. Recent genomic profiling has highlighted circular RNA MCM3, or circMCM3, as an important regulator of malignant behavior. Specifically, researchers detected substantial circMCM3 upregulation in platinum-resistant tumour tissue compared to chemo-sensitive samples.

Moreover, clinical analyses demonstrate that elevated circMCM3 expression correlates directly with shortened patient survival and poor prognostic indicators. Functional assays show that circMCM3 actively drives cisplatin resistance in vitro and in vivo. Tumour cells expressing high circMCM3 levels maintain robust cell proliferation despite cytotoxic exposure. Furthermore, these cells display reduced apoptotic rates and markedly fewer platinum-induced DNA breaks. Thus, circMCM3 operates as an active oncogenic driver that insulates malignant cells from chemotherapy-mediated cytotoxicity.

Mechanistic Crosstalk: circMCM3 Recruits USP49 to Stabilize PTBP1

To uncover the molecular mechanism, investigators explored the direct binding partners of circMCM3. Their experiments revealed that circMCM3 binds directly to ubiquitin-specific protease 49, an active deubiquitinating enzyme designated as USP49. Typically, cellular proteins undergo ubiquitination to mark them for rapid proteasomal clearance. However, circMCM3 recruits USP49 to prevent this enzymatic degradation on target proteins.

In particular, this molecular complex stabilizes polypyrimidine tract-binding protein 1, commonly termed PTBP1. Under baseline cellular conditions, PTBP1 undergoes continuous ubiquitin-dependent breakdown. In contrast, circMCM3-tethered USP49 removes ubiquitin chains from PTBP1, extending its protein half-life. PTBP1 functions as a crucial RNA-binding protein that orchestrates RNA processing, alternative splicing, and translational efficiency. Notably, experimental silencing of USP49 abolishes this protective deubiquitination, prompting rapid PTBP1 turnover even when circMCM3 is present. This demonstrates how a circular RNA directly coordinates post-translational machinery to protect critical oncogenic proteins.

CCND1 mRNA Stabilization Drives Cell Cycle Progression

Once stabilized, PTBP1 exerts widespread downstream effects on cellular transcription and survival cascades. Specifically, PTBP1 binds directly to the messenger RNA of CCND1, which encodes the cell cycle regulator cyclin D1. Under physiological conditions, cells tightly control CCND1 transcript stability to prevent aberrant mitosis. However, PTBP1 binding protects CCND1 mRNA from degradation, causing substantial accumulation of cyclin D1 protein.

Consequently, elevated cyclin D1 accelerates the transition of cancer cells from G1 into S phase. This sustained cycle progression allows malignant cells to bypass platinum-induced cell cycle arrest checkpoints. Furthermore, cells expressing elevated cyclin D1 repair replication stress more effectively, substantially reducing measurable DNA damage. Notably, experimental depletion of either PTBP1 or CCND1 completely abrogates circMCM3-mediated cisplatin resistance. Therefore, the functional circMCM3-USP49-PTBP1-CCND1 axis forms an indispensable pathway that shields squamous tumour cells against platinum toxicity.

Therapeutic Innovations for Cervical Squamous Cell Carcinoma

Identifying the circMCM3-USP49-PTBP1-CCND1 axis uncovers exciting translational possibilities for managing therapy-resistant cervical squamous cell carcinoma. Clinicians currently lack targeted salvage therapies once standard chemoradiation regimens fail. However, disrupting key nodes within this newly identified cascade could re-sensitize recalcitrant tumours to platinum compounds. For instance, developing small molecules that disrupt the circMCM3-USP49 interaction could restore proteasomal degradation of PTBP1.

Similarly, pharmacological USP49 inhibitors or downstream cyclin-dependent kinase inhibitors represent promising combinatorial partners. Combining such targeted agents with cisplatin could lower necessary chemotherapy doses, minimizing nephrotoxicity and neurotoxicity. Furthermore, circMCM3 serves as an accessible candidate biomarker for risk stratification. Detecting elevated circMCM3 in baseline biopsies or circulating exosomes could alert oncologists to imminent chemoresistance. Consequently, clinicians could modify systemic protocols early, utilizing immunotherapy or alternative agents to improve survival in high-risk patients.

Translational Relevance for Clinical Practice in India

These findings hold profound clinical importance for oncologists practicing in high-burden regions like India. Gynaecological cancers continue to place immense physical and financial distress on patients and public healthcare systems. Because late-stage presentation remains widespread, platinum resistance leads directly to rapid treatment failure. Therefore, implementing cost-effective molecular testing for markers like circMCM3 could enhance treatment stratification across Indian cancer centres.

In addition, domestic research initiatives can leverage these insights to explore indigenous drug development targeting deubiquitinases or RNA-protein complexes. Incorporating liquid biopsy platforms could enable non-invasive monitoring of therapeutic response during concurrent chemoradiotherapy cycles. Ultimately, translating fundamental non-coding RNA discoveries into actionable bedside protocols will empower clinicians to overcome drug resistance, personalize treatment algorithms, and achieve superior clinical outcomes for women facing aggressive cervical tumours.

Frequently Asked Questions

What is circMCM3 and how does it influence cervical cancer progression?

Circular RNA MCM3, or circMCM3, is a stable non-coding RNA molecule derived from the MCM3 gene locus. Because of its closed circular configuration, it resists enzymatic degradation inside cells. In cervical oncology, circMCM3 is significantly upregulated in cisplatin-resistant tumours and associates with poor patient prognosis. It actively accelerates cellular proliferation, suppresses apoptosis, and reduces chemotherapy-induced DNA damage, thereby driving platinum resistance.

How does the USP49-PTBP1-CCND1 axis mediate resistance to cisplatin?

The circMCM3 transcript recruits the deubiquitinase USP49, which removes ubiquitin chains from PTBP1 to prevent its proteasomal destruction. Consequently, stabilized PTBP1 binds to and stabilizes CCND1 messenger RNA, elevating cyclin D1 protein levels. Cyclin D1 promotes rapid G1 to S phase cell cycle progression, bypassing cisplatin-induced arrest checkpoints. This functional cascade mitigates platinum genotoxicity, enabling tumour cells to survive despite chemotherapy assault.

What therapeutic opportunities emerge from targeting non-coding RNA pathways?

Targeting the circMCM3 pathway provides viable opportunities to re-sensitize resistant squamous tumours to standard platinum agents. Preclinical experiments confirm that genetic knockdown of PTBP1 or CCND1 completely eliminates circMCM3-driven chemoresistance. Therefore, developing small-molecule deubiquitinase inhibitors or antisense oligonucleotides against circMCM3 could restore drug sensitivity. Combining these targeted interventions with cisplatin-based chemotherapy may significantly improve treatment efficacy while reducing required chemotherapy dosages.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Zhu C et al. Circular RNA MCM3 recruits USP49 to stabilize PTBP1 and promote cisplatin resistance in cervical squamous cell carcinoma. Oncogene. 2026 Sep 12. doi: 10.1038/s41388-026-03988-2. PMID: 42728347.


2. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):28-44.


3. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869-1883.


4. Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675-691.